Cannabics Pharmaceuticals Inc (OTCQB:CNBX). (OTCQB:CNBX) Co-founder and CEO Eyal Barad tells Proactive the Tel Aviv, Israel-based developer of cancer related cannabinoid-based medicines has filed two new provisional patent applications on its methods for treating cancer, including colorectal cancer.
Barad says the patent covers its involvement in pre-surgery stage and before or during chemotherapy and radian therapy, hoping to help downstage the development of cancer post-surgery. It expects to begin its Phase 1/2a in human studies in 2022.